BioSpace News Archive

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren’s disease: a localized and accessible human fibrotic disorder’ in the journal Trends in Molecular Medicine.

Vericel Corporation today announced that Nick Colangelo, President and CEO will present at the 41st Annual J.P. Morgan Healthcare Conference.

Mirion Technologies, Inc. (NYSE: MIR) announced today that Chief Executive Officer, Thomas Logan, and Chief Financial Officer, Brian Schopfer, will present at the CJS Securities 23rd Annual New Ideas for the New Year Conference.

Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.

Heart Test Laboratories, Inc. d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG a far more valuable screening tool through the use of Artificial Intelligence, announced it has appointed David R. Wells to its Board of Directors, effective December 28, 2022.

Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 4:30 p.m. Pacific Time.

UroDev Medical, a medical device company working to improve the quality of life for people who suffer from neurogenic bladder and chronic urinary retention, recently announced the appointment of Jayme Hanson to its board of directors.

Elixirgen Therapeutics, Inc. announced that members of the management team will be attending the Biotech Showcase Conference taking place January 9-11, 2023 in San Francisco, California.

Tenax Therapeutics, Inc. announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20.